Clinical Trial Update: Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients [Phase 2]

View source ↗

Summary

Results from an extension Phase 2 study of the iron chelator deferasirox in patients with β-thalassemia and other rare chronic anemias have been posted. The rep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Hemosiderosis
• Thalassemia

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Anemia, Hemosiderosis | Phase 2 | Status: COMPLETED | Results posted: 2011-05-09